These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23965729)

  • 1. Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA.
    Fiebelkorn AP; Lawler J; Curns AT; Brandeburg C; Wallace GS
    Emerg Infect Dis; 2013; 19(9):1411-7. PubMed ID: 23965729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.
    Nelson GE; Aguon A; Valencia E; Oliva R; Guerrero ML; Reyes R; Lizama A; Diras D; Mathew A; Camacho EJ; Monforte MN; Chen TH; Mahamud A; Kutty PK; Hickman C; Bellini WJ; Seward JF; Gallagher K; Fiebelkorn AP
    Pediatr Infect Dis J; 2013 Apr; 32(4):374-80. PubMed ID: 23099425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak.
    Ogbuanu IU; Kutty PK; Hudson JM; Blog D; Abedi GR; Goodell S; Lawler J; McLean HQ; Pollock L; Rausch-Phung E; Schulte C; Valure B; Armstrong GL; Gallagher K
    Pediatrics; 2012 Dec; 130(6):e1567-74. PubMed ID: 23129075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.
    Cardemil CV; Dahl RM; James L; Wannemuehler K; Gary HE; Shah M; Marin M; Riley J; Feikin DR; Patel M; Quinlisk P
    N Engl J Med; 2017 Sep; 377(10):947-956. PubMed ID: 28877026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City.
    Livingston KA; Rosen JB; Zucker JR; Zimmerman CM
    Vaccine; 2014 Jan; 32(3):369-74. PubMed ID: 24252695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
    Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013.
    Arciuolo RJ; Jablonski RR; Zucker JR; Rosen JB
    Clin Infect Dis; 2017 Nov; 65(11):1843-1847. PubMed ID: 29028959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 18. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing outbreak of mumps infection in Oban, Scotland, November 2010 to January 2011.
    Walker J; Huc S; Sinka K; Tissington A; Oates K
    Euro Surveill; 2011 Feb; 16(8):. PubMed ID: 21371413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.